Please assess the completion status of the following clinical trial:

Trial Title: Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* critically ill adults~* RASS score of -3 to 0 after receiving benzodiazepine therapy~* CAM-ICU positive~* no benzodiazepine therapy within the previous 12 hours~Exclusion Criteria:~1. contraindications to flumazenil including hypersensitivity~2. receipt of benzodiazepines for control of potentially life-threatening conditions (e.g., control of intracranial pressure or status epilepticus)~3. active seizure disorder or on current anti-convulsant therapy for history of seizure disorder. Seizures secondary to alcohol withdrawal will NOT be excluded.~4. history of traumatic brain injury complicated by seizures~5. acute episode (within prior 30 days) of severe traumatic brain injury~6. history of structural lesion (e.g. subarachnoid hemorrhage, cerebrovascular accident, intra-parenchymal hemorrhage) complicated by seizures~7. acute episode (within prior 14 days) of structural lesion (e.g. subarachnoid hemorrhage, cerebrovascular accident, intra-parenchymal hemorrhage)~8. brain tumor complicated by seizure~9. history of anoxic brain injury~10. third-degree burn with total body surface area (TBSA) burn greater than 20%~11. chronic benzodiazepine (clonazepam:lorazepam:diazepam approximately 4:8:40 mg per day) for 7 consecutive days with no taper~12. chronic delirium that is attributable to other causes~13. anticipated to transfer to lower level of care within 24 hours~14. admitted for polysubstance overdose as determined by initial drug toxicity screening~15. recent exposure (prior 7 days) to pro-convulsant medications (identified via medication list, medication reconciliation performed by PI/pharmacy medication reconciliation team, or urine drug screening)~16. children, incarcerated individuals, and pregnant women~17. unable to provide consent and the legally authorized representative is unable to provide consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Flumazenil Infusion (Type: ACTIVE_COMPARATOR): The flumazenil continuous infusion is started at an initial dose of 0.1 mg/hr., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.
- Placebo Infusion (Type: PLACEBO_COMPARATOR): The placebo continuous infusion is started at an initial dose of 0.1 mg/hr (2 ml/hr)., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.

Based on this trial design, predict the completion outcome and termination type (if applicable).